JP2021522242A5 - - Google Patents

Info

Publication number
JP2021522242A5
JP2021522242A5 JP2020559394A JP2020559394A JP2021522242A5 JP 2021522242 A5 JP2021522242 A5 JP 2021522242A5 JP 2020559394 A JP2020559394 A JP 2020559394A JP 2020559394 A JP2020559394 A JP 2020559394A JP 2021522242 A5 JP2021522242 A5 JP 2021522242A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
ring
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559394A
Other languages
English (en)
Japanese (ja)
Other versions
JP7304892B2 (ja
JP2021522242A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028607 external-priority patent/WO2019209759A1/en
Publication of JP2021522242A publication Critical patent/JP2021522242A/ja
Publication of JP2021522242A5 publication Critical patent/JP2021522242A5/ja
Priority to JP2023092450A priority Critical patent/JP2023101824A/ja
Application granted granted Critical
Publication of JP7304892B2 publication Critical patent/JP7304892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559394A 2018-04-24 2019-04-23 抗増殖性化合物およびその使用 Active JP7304892B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023092450A JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661719P 2018-04-24 2018-04-24
US62/661,719 2018-04-24
PCT/US2019/028607 WO2019209759A1 (en) 2018-04-24 2019-04-23 Antiproliferation compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023092450A Division JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2021522242A JP2021522242A (ja) 2021-08-30
JP2021522242A5 true JP2021522242A5 (cg-RX-API-DMAC7.html) 2022-04-13
JP7304892B2 JP7304892B2 (ja) 2023-07-07

Family

ID=66655429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559394A Active JP7304892B2 (ja) 2018-04-24 2019-04-23 抗増殖性化合物およびその使用
JP2023092450A Pending JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023092450A Pending JP2023101824A (ja) 2018-04-24 2023-06-05 抗増殖性化合物およびその使用

Country Status (26)

Country Link
US (4) US10815225B2 (cg-RX-API-DMAC7.html)
EP (2) EP3784666B1 (cg-RX-API-DMAC7.html)
JP (2) JP7304892B2 (cg-RX-API-DMAC7.html)
KR (1) KR102813581B1 (cg-RX-API-DMAC7.html)
CN (1) CN112236428B (cg-RX-API-DMAC7.html)
AR (1) AR114496A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019261308B2 (cg-RX-API-DMAC7.html)
CA (1) CA3098335A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125433T1 (cg-RX-API-DMAC7.html)
DK (2) DK3784666T3 (cg-RX-API-DMAC7.html)
ES (2) ES2987356T3 (cg-RX-API-DMAC7.html)
FI (1) FI4043460T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241163T1 (cg-RX-API-DMAC7.html)
HU (2) HUE058746T2 (cg-RX-API-DMAC7.html)
IL (2) IL301501B2 (cg-RX-API-DMAC7.html)
LT (1) LT3784666T (cg-RX-API-DMAC7.html)
MX (1) MX2020011089A (cg-RX-API-DMAC7.html)
PL (2) PL3784666T3 (cg-RX-API-DMAC7.html)
PT (2) PT4043460T (cg-RX-API-DMAC7.html)
RS (1) RS63281B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009500QA (cg-RX-API-DMAC7.html)
SI (1) SI3784666T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200308T1 (cg-RX-API-DMAC7.html)
TW (1) TWI813673B (cg-RX-API-DMAC7.html)
WO (1) WO2019209759A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006071B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301501B2 (en) 2018-04-24 2024-10-01 Vertex Pharma Antiproliferation compounds and uses thereof
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020236834A1 (en) * 2019-05-20 2020-11-26 Seshadri Raju Modified z stents for iliac vein stenting
CN115103840B (zh) 2019-12-20 2025-07-22 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
US20240132464A1 (en) * 2022-09-28 2024-04-25 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
WO2025223536A1 (zh) * 2024-04-26 2025-10-30 正大天晴药业集团股份有限公司 稠合双环化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE19840028A1 (de) 1998-09-02 2000-03-09 Max Planck Gesellschaft Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
US8163763B2 (en) 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
CN102753528A (zh) * 2009-12-04 2012-10-24 霍夫曼-拉罗奇有限公司 作为单胺重摄取抑制剂的二苯基氮杂*衍生物
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3256132A1 (en) 2015-02-13 2017-12-20 Merck Patent GmbH Pyrimidine derivatives for use in the treatment of cancer
IL301501B2 (en) 2018-04-24 2024-10-01 Vertex Pharma Antiproliferation compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2023511337A5 (cg-RX-API-DMAC7.html)
JP2021522237A5 (cg-RX-API-DMAC7.html)
AR044403A1 (es) Derivados de oximas y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
JP2018536648A5 (cg-RX-API-DMAC7.html)
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PE20220140A1 (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
HRP20220710T1 (hr) Antiproliferacijski spojevi i njihova uporaba
RU2016126503A (ru) Аналоги кортистатина, их синтез и применения
JP2018535963A5 (cg-RX-API-DMAC7.html)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
JP2016513130A5 (cg-RX-API-DMAC7.html)
JP2022514315A5 (cg-RX-API-DMAC7.html)
RU2018102365A (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
JP2023520330A5 (cg-RX-API-DMAC7.html)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
JP2016503797A5 (cg-RX-API-DMAC7.html)
JP2022505645A5 (cg-RX-API-DMAC7.html)
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2008517923A5 (cg-RX-API-DMAC7.html)
JP2019519616A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине